Cargando…

Tau physiology and pathomechanisms in frontotemporal lobar degeneration

Frontotemporal lobar degeneration (FTLD) has been associated with toxic intracellular aggregates of hyperphosphorylated tau (FTLD‐tau). Moreover, genetic studies identified mutations in the MAPT gene encoding tau in familial cases of the disease. In this review, we cover a range of aspects of tau fu...

Descripción completa

Detalles Bibliográficos
Autores principales: Bodea, Liviu‐Gabriel, Eckert, Anne, Ittner, Lars Matthias, Piguet, Olivier, Götz, Jürgen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5094566/
https://www.ncbi.nlm.nih.gov/pubmed/27306859
http://dx.doi.org/10.1111/jnc.13600
_version_ 1782465128150597632
author Bodea, Liviu‐Gabriel
Eckert, Anne
Ittner, Lars Matthias
Piguet, Olivier
Götz, Jürgen
author_facet Bodea, Liviu‐Gabriel
Eckert, Anne
Ittner, Lars Matthias
Piguet, Olivier
Götz, Jürgen
author_sort Bodea, Liviu‐Gabriel
collection PubMed
description Frontotemporal lobar degeneration (FTLD) has been associated with toxic intracellular aggregates of hyperphosphorylated tau (FTLD‐tau). Moreover, genetic studies identified mutations in the MAPT gene encoding tau in familial cases of the disease. In this review, we cover a range of aspects of tau function, both in the healthy and diseased brain, discussing several in vitro and in vivo models. Tau structure and function in the healthy brain is presented, accentuating its distinct compartmentalization in neurons and its role in microtubule stabilization and axonal transport. Furthermore, tau‐driven pathology is discussed, introducing current concepts and the underlying experimental evidence. Different aspects of pathological tau phosphorylation, the protein's genomic and domain organization as well as its spreading in disease, together with MAPT‐associated mutations and their respective models are presented. Dysfunction related to other post‐transcriptional modifications and their effect on normal neuronal functions such as cell cycle, epigenetics and synapse dynamics are also discussed, providing a mechanistic explanation for the observations made in FTLD‐tau cases, with the possibility for therapeutic intervention. [Image: see text] In this review, we cover aspects of tau function, both in the healthy and diseased brain, referring to different in vitro and in vivo models. In healthy neurons, tau is compartmentalized, with higher concentrations found in the distal part of the axon. Cargo molecules are sensitive to this gradient. A disturbed tau distribution, as found in frontotemporal lobar degeneration (FTLD‐tau), has severe consequences for cellular physiology: tau accumulates in the neuronal soma and dendrites, leading among others to microtubule depolymerization and impaired axonal transport. Tau forms insoluble aggregates that sequester additional molecules stalling cellular physiology. Neuronal communication is gradually lost as toxic tau accumulates in dendritic spines with subsequent degeneration of synapses and synaptic loss. Thus, by providing a mechanistic explanation for the observations made in FTLD‐tau cases, arises a possibility for therapeutic interventions. This article is part of the Frontotemporal Dementia special issue.
format Online
Article
Text
id pubmed-5094566
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-50945662016-11-09 Tau physiology and pathomechanisms in frontotemporal lobar degeneration Bodea, Liviu‐Gabriel Eckert, Anne Ittner, Lars Matthias Piguet, Olivier Götz, Jürgen J Neurochem Frontotemporal dementias: From molecular mechanisms to therapy Frontotemporal lobar degeneration (FTLD) has been associated with toxic intracellular aggregates of hyperphosphorylated tau (FTLD‐tau). Moreover, genetic studies identified mutations in the MAPT gene encoding tau in familial cases of the disease. In this review, we cover a range of aspects of tau function, both in the healthy and diseased brain, discussing several in vitro and in vivo models. Tau structure and function in the healthy brain is presented, accentuating its distinct compartmentalization in neurons and its role in microtubule stabilization and axonal transport. Furthermore, tau‐driven pathology is discussed, introducing current concepts and the underlying experimental evidence. Different aspects of pathological tau phosphorylation, the protein's genomic and domain organization as well as its spreading in disease, together with MAPT‐associated mutations and their respective models are presented. Dysfunction related to other post‐transcriptional modifications and their effect on normal neuronal functions such as cell cycle, epigenetics and synapse dynamics are also discussed, providing a mechanistic explanation for the observations made in FTLD‐tau cases, with the possibility for therapeutic intervention. [Image: see text] In this review, we cover aspects of tau function, both in the healthy and diseased brain, referring to different in vitro and in vivo models. In healthy neurons, tau is compartmentalized, with higher concentrations found in the distal part of the axon. Cargo molecules are sensitive to this gradient. A disturbed tau distribution, as found in frontotemporal lobar degeneration (FTLD‐tau), has severe consequences for cellular physiology: tau accumulates in the neuronal soma and dendrites, leading among others to microtubule depolymerization and impaired axonal transport. Tau forms insoluble aggregates that sequester additional molecules stalling cellular physiology. Neuronal communication is gradually lost as toxic tau accumulates in dendritic spines with subsequent degeneration of synapses and synaptic loss. Thus, by providing a mechanistic explanation for the observations made in FTLD‐tau cases, arises a possibility for therapeutic interventions. This article is part of the Frontotemporal Dementia special issue. John Wiley and Sons Inc. 2016-06-15 2016-08 /pmc/articles/PMC5094566/ /pubmed/27306859 http://dx.doi.org/10.1111/jnc.13600 Text en © 2016 The Authors. Journal of Neurochemistry published by John Wiley & Sons Ltd on behalf of International Society for Neurochemistry This is an open access article under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Frontotemporal dementias: From molecular mechanisms to therapy
Bodea, Liviu‐Gabriel
Eckert, Anne
Ittner, Lars Matthias
Piguet, Olivier
Götz, Jürgen
Tau physiology and pathomechanisms in frontotemporal lobar degeneration
title Tau physiology and pathomechanisms in frontotemporal lobar degeneration
title_full Tau physiology and pathomechanisms in frontotemporal lobar degeneration
title_fullStr Tau physiology and pathomechanisms in frontotemporal lobar degeneration
title_full_unstemmed Tau physiology and pathomechanisms in frontotemporal lobar degeneration
title_short Tau physiology and pathomechanisms in frontotemporal lobar degeneration
title_sort tau physiology and pathomechanisms in frontotemporal lobar degeneration
topic Frontotemporal dementias: From molecular mechanisms to therapy
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5094566/
https://www.ncbi.nlm.nih.gov/pubmed/27306859
http://dx.doi.org/10.1111/jnc.13600
work_keys_str_mv AT bodealiviugabriel tauphysiologyandpathomechanismsinfrontotemporallobardegeneration
AT eckertanne tauphysiologyandpathomechanismsinfrontotemporallobardegeneration
AT ittnerlarsmatthias tauphysiologyandpathomechanismsinfrontotemporallobardegeneration
AT piguetolivier tauphysiologyandpathomechanismsinfrontotemporallobardegeneration
AT gotzjurgen tauphysiologyandpathomechanismsinfrontotemporallobardegeneration